The 'hit-and-run' strategy and viral carcinogenesis
Future Oncol
.
2023 Feb;19(5):341-344.
doi: 10.2217/fon-2022-1171.
Epub 2023 Mar 15.
Authors
Angioletta Lasagna
1
,
Irene Cassaniti
2
,
Paolo Sacchi
3
,
Simone Figini
1
,
Fausto Baldanti
2
4
,
Raffaele Bruno
3
4
,
Paolo Pedrazzoli
1
5
Affiliations
1
Medical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, Viale Camillo Golgi 19, Pavia, 27100, Italy.
2
Department of Microbiology & Virology, Fondazione IRCCS Policlinico San Matteo, Viale Camillo Golgi 19, Pavia, 27100, Italy.
3
Division of Infectious Diseases I, Fondazione IRCCS Policlinico San Matteo, Viale Camillo Golgi 19, Pavia, 27100, Italy.
4
Department of Clinical Surgical Diagnostic & Pediatric Sciences, University of Pavia, Viale Camillo Golgi 19, Pavia, 27100, Italy.
5
Department of Internal Medicine & Medical Therapy, University of Pavia, Viale Camillo Golgi 19, Pavia, 27100, Italy.
PMID:
36919920
DOI:
10.2217/fon-2022-1171
No abstract available
Keywords:
EBV; HBV; cancer; herpes virus; hit-and-run; vaccination; viral infection; virome.
MeSH terms
Carcinogenesis* / genetics
Herpesvirus 4, Human*
Humans